Abstract
The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p1c), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p
| Original language | English |
|---|---|
| Pages (from-to) | 917-924 |
| Number of pages | 8 |
| Journal | Hypertension Research |
| Volume | 28 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2005 |
Fingerprint
Keywords
- Glimepiride
- Metabolic syndrome
- Pioglitazone
- Rosiglitazone
- Thiazolidinediones
ASJC Scopus subject areas
- Internal Medicine
Cite this
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. / Derosa, Giuseppe; Cicero, Arrigo Francesco Giuseppe; D'Angelo, Angela; Gaddi, Antonio; Ragonesi, Pietro Dario; Piccinni, Mario Nello; Salvadeo, Sibilla; Ciccarelli, Leonardina; Pricolo, Fabio; Ghelfi, Morena; Ferrari, Ilaria; Montagna, Lorenza; Fogari, Roberto.
In: Hypertension Research, Vol. 28, No. 11, 11.2005, p. 917-924.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride
AU - Derosa, Giuseppe
AU - Cicero, Arrigo Francesco Giuseppe
AU - D'Angelo, Angela
AU - Gaddi, Antonio
AU - Ragonesi, Pietro Dario
AU - Piccinni, Mario Nello
AU - Salvadeo, Sibilla
AU - Ciccarelli, Leonardina
AU - Pricolo, Fabio
AU - Ghelfi, Morena
AU - Ferrari, Ilaria
AU - Montagna, Lorenza
AU - Fogari, Roberto
PY - 2005/11
Y1 - 2005/11
N2 - The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p1c), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p
AB - The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p1c), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p
KW - Glimepiride
KW - Metabolic syndrome
KW - Pioglitazone
KW - Rosiglitazone
KW - Thiazolidinediones
UR - http://www.scopus.com/inward/record.url?scp=31744442785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31744442785&partnerID=8YFLogxK
U2 - 10.1291/hypres.28.917
DO - 10.1291/hypres.28.917
M3 - Article
VL - 28
SP - 917
EP - 924
JO - Hypertension Research
JF - Hypertension Research
SN - 0916-9636
IS - 11
ER -